|Articles|July 11, 2017

Meropenem For Ceftazidime-Avibactam—Resistant K. pneumoniae

Researchers from the University of Pittsburgh find a way to successfully treat a patient with ceftazidime-avibactam-resistant Klebsiella pneumoniae.

Clinicians used meropenem to successfully treat a patient with bacteremia due to Klebsiella pneumoniae that carried a mutation in the blaKPC-3 gene, and was resistant to ceftazidime-avibactam.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.